The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine

被引：13
|
作者：
Djimde, Abdoulaye A. [1 ]
Makanga, Michael [2 ]
Kuhen, Kelli [3 ]
Hamed, Kamal [4 ]
机构：
[1] Univ Sci Tech & Technol Bamako, Malaria Res & Training Ctr, Bamako, Mali
[2] European & Developing Countries Clin Trials Partn, Cape Town, South Africa
[3] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA
[4] Novartis Pharmaceut, E Hanover, NJ 07936 USA
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2015年 / 13卷 / 08期
关键词：
artemether-lumefantrine; artemisinin resistance; clinical efficacy; molecular markers; systematic review; PLASMODIUM-FALCIPARUM MALARIA; ARTESUNATE PLUS AMODIAQUINE; PFMDR1 COPY NUMBER; IN-VIVO EFFICACY; ANTIMALARIAL-DRUG RESISTANCE; VITRO-REDUCED SUSCEPTIBILITY; FIXED-DOSE COMBINATION; THAN; YEARS; UNCOMPLICATED MALARIA; DIHYDROARTEMISININ-PIPERAQUINE;
D O I：
10.1586/14787210.2015.1052793
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The development of artemisinin resistance in the Greater Mekong Subregion poses a significant threat to malaria elimination. Artemisinin-based combination therapies including artemether-lumefantrine (AL) are recommended by WHO as first-line treatment for uncomplicated Plasmodium falciparum malaria. This article provides a comprehensive review of the existing and latest data as a basis for interpretation of observed variability in parasite sensitivity to AL over the last 5 years. Clinical efficacy and preclinical data from a range of endemic countries are summarized, including potential molecular markers of resistance. Overall, AL remains effective in the treatment of uncomplicated P. falciparum malaria in most regions. Establishing validated molecular markers for resistance and strict efficacy monitoring will reinforce timely updates of treatment policies.
引用
收藏
页码：1031 / 1045
页数：15
相关论文
共 50 条
  • [31] Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria
    Tchaparian, Eskouhie
    Sambol, Nancy C.
    Arinaitwe, Emmanuel
    McCormack, Shelley A.
    Bigira, Victor
    Wanzira, Humphrey
    Muhindo, Mary
    Creek, Darren J.
    Sukumar, Nitin
    Blessborn, Daniel
    Tappero, Jordan W.
    Kakuru, Abel
    Bergqvist, Yngve
    Aweeka, Francesca T.
    Parikh, Sunil
    JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (08): : 1243 - 1251
  • [32] Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia
    Denis, Mey Bouth
    Tsuyuoka, Reiko
    Lim, Pharath
    Lindegardh, Niklas
    Yi, Poravuth
    Top, Sophoan Narann
    Socheat, Duong
    Fandeur, Thierry
    Annerberg, Anna
    Christophel, Eva Maria
    Ringwald, Pascal
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2006, 11 (12) : 1800 - 1807
  • [33] Therapeutic Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia
    Ippolito, Matthew
    Pringle, Julia
    Siame, Mwiche
    Katowa, Ben
    Aydemir, Ozkan
    Oluoch, Peter
    Huang, Liusheng
    Aweeka, Francesca
    Bailey, Jeffrey
    Juliano, Jonathan
    Meshnick, Steven
    Shapiro, Theresa
    Moss, William
    Thuma, Philip
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2020, 103 (06): : 2224 - 2232
  • [34] Retrospective observational study of the use of artemether-lumefantrine in the treatment of malaria in Japan
    Nakamura-Uchiyama, Fukumi
    Katanami, Yuichi
    Kikuchi, Tadashi
    Takaya, Saho
    Kutsuna, Satoshi
    Kobayashi, Taiichiro
    Mizuno, Yasutaka
    Hasegawa, Tetsuo
    Koga, Michiko
    Yoshimura, Yukihiro
    Hasegawa, Chihiro
    Kato, Yasuyuki
    Kimura, Mikio
    Maruyama, Haruhiko
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2018, 22 : 40 - 45
  • [35] Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria
    Tarning, Joel
    von Seidlein, Lorenz
    Dondorp, Arjen M.
    White, Nicholas J.
    Maude, Richard J.
    BMC RESEARCH NOTES, 2022, 15 (01)
  • [36] Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?
    Bernhards Ogutu
    Alfred B Tiono
    Michael Makanga
    Zulfiqarali Premji
    Adama Dodji Gbadoé
    David Ubben
    Anne Claire Marrast
    Oumar Gaye
    Malaria Journal, 9
  • [37] Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania
    Mugoyela, V.
    Minzi, O.
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2011, 4 : 89 - 95
  • [38] Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Nepal
    Ghimire P.
    Rijal K.R.
    Kafle C.
    Karki B.S.
    Singh N.
    Ortega L.
    Thakur G.D.
    Adhikari B.
    Tropical Diseases, Travel Medicine and Vaccines, 4 (1)
  • [39] Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria
    Bassat, Quique
    Ogutu, Bernhards
    Djimde, Abdoulaye
    Stricker, Kirstin
    Hamed, Kamal
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4366 - 4374
  • [40] Monitoring the efficacy of artemether-lumefantrine for the treatment of uncomplicated malaria in Malawian children
    Rosalia Dambe
    John Sande
    Doreen Ali
    Ben Chilima
    Wilfred Dodoli
    Charles Michelo
    Grace Malenga
    Kamija S Phiri
    Malaria Journal, 14
12345